Lv31
260 积分 2023-08-25 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
24天前
已完结
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
1个月前
已完结
Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis
1个月前
已关闭
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
4个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
4个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1年前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
1年前
已完结
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
1年前
已完结
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
1年前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1年前
已完结
皖公网安备34019202002308
